ADMA BIOLOGICS, INC.

ADMA

ADMA BIOLOGICS, INC.

ADMA

Insider Sentiment (TTM):

Last Purchase:2026-05-27Last Sale:2026-03-16Shares Purchased (TTM):38,400Shares Sold (TTM):157,096

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:203,553,999Shares Outstanding:236,072,751Institutional Ownership Pct.:86.23%

Earnings Market Reaction:

Filing Date:2026-05-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Biological Products, (No Diagnostic Substances)

AMGN GILD SCLX BIIB MRNA RVMD

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	138	88	61	90	72	103	87	88	45	51	74	63
Accounts Receivable Net Current	136	158	138	110	99	50	50	30	50	27	31	37
Inventory Net	222	206	197	191	172	170	172	180	178	173	163	162
Prepaid Expense And Other Assets Current	15	7	7	8	9	8	10	6	4	5	5	5
Assets Held For Sale Not Part Of Disposal Group Cu…	0	7	-	-	-	0	-	-	-	-	-	-
Assets Current	511	467	403	400	352	331	318	304	276	257	274	266
Property Plant And Equipment Net	65	65	70	58	58	55	54	54	55	54	55	56
Intangible Assets Net Excluding Goodwill	1	1	0	1	0	0	0	0	0	0	0	1
Goodwill	4	4	4	4	4	4	4	4	4	4	4	4
Deferred Income Tax Assets Net	70	73	74	79	81	84	-	-	-	0	-	-
Operating Lease Right Of Use Asset	6	7	9	9	8	9	9	9	9	10	10	10
Assets	665	624	569	558	511	489	391	376	351	329	349	343
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	21	23	24	30	21	20	16	14	17	16	11	12
Accrued Liabilities And Other Liabilities	49	40	29	44	32	34	28	28	34	33	30	29
Contract With Customer Liability Current	-	-	-	0	0	0	0	1	1	0	0	0
Long Term Debt Current	3	3	2	-	-	0	-	-	-	-	-	-
Operating Lease Liability Current	1	1	1	1	1	1	1	1	1	1	1	1
Liabilities Of Disposal Group Including Discontinu…	0	3	-	-	-	0	-	-	-	-	-	-
Liabilities Current	74	70	56	75	53	56	45	44	53	50	42	42
Senior Long Term Notes	-	-	-	73	73	72	101	131	131	131	142	140
Long Term Debt Noncurrent	194	69	70	-	-	72	-	-	-	-	-	-
Deferred Revenue Noncurrent	1	1	1	1	2	2	2	2	2	2	2	2
Operating Lease Liability Noncurrent	6	7	9	9	8	9	9	9	9	10	10	10
Other Liabilities Noncurrent	-	0	0	0	0	0	0	0	0	0	0	0
Liabilities	275	147	138	160	137	140	159	188	197	194	198	196
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Treasury Stock Value	-143	-32	-23	-15	-	0	-	0	-	-	-	-
Additional Paid In Capital	650	671	665	661	655	658	652	645	642	641	640	638
Retained Earnings Accumulated Deficit	-116	-162	-211	-247	-282	-309	-420	-456	-488	-506	-489	-491
Stockholders Equity	390	477	431	398	373	349	232	188	154	135	151	147
Liabilities And Stockholders Equity	665	624	569	558	511	489	391	376	351	329	349	343
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	300	300	300	300	300	300	300	300	300	300	300	300
Shares Outstanding	232	238	238	239	239	237	236	233	232	226	226	225
Common Stock Shares Issued	241	240	240	239	239	237	236	233	232	226	226	225
Treasury Stock Common Shares	9	2	1	1	-	0	-	0	-	-	-	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-20.83%	-13.19%	-17.96%	-	-	-	-	-	-	-	-	-
2025	-15.97%	-23.08%	-23.72%	-6.90%	-15.80%	-18.12%	24.79%	25.44%	8.85%	-8.67%	-29.78%	-47.26%
2024	37.81%	61.33%	89.90%	42.00%	59.02%	29.70%	1.98%	-11.51%	-18.46%	3.69%	6.79%	10.16%
2023	13.45%	3.36%	12.89%	-4.19%	-11.82%	-18.47%	5.25%	24.86%	40.61%	16.91%	16.54%	71.19%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	6.95	6.71	7.13	5.33	6.58	5.97	7.09	6.87	5.21	5.16	6.54	6.35
Quick Ratio	3.73	3.63	3.52	2.67	3.20	2.76	3.05	2.68	1.79	1.58	2.52	2.37
Working Capital	437.63M	396.97M	346.17M	324.62M	298.32M	275.87M	273.30M	259.51M	223.33M	207.21M	231.86M	224.29M
Leverage & Debt
Debt to Equity	0.70	0.31	0.32	0.40	0.37	0.40	0.68	1.00	1.28	1.43	1.30	1.34
Interest Coverage TTM	29.69	26.93	19.97	15.28	12.53	9.98	6.65	4.16	1.95	0.86	0.05	-0.70
Debt Ratio	0.41	0.24	0.24	0.29	0.27	0.29	0.41	0.50	0.56	0.59	0.57	0.57
Efficiency & Turnover
Asset Turnover TTM	0.87	0.92	1.02	1.01	1.07	1.04	1.04	0.92	0.82	0.76	0.72	0.65
Days Sales Outstanding TTM	84.21	74.56	70.16	53.82	59.21	33.13	38.83	36.94	49.07	30.34	40.68	48.77
Receivables Turnover TTM	4.33	4.90	5.20	6.78	6.16	11.02	9.40	9.88	7.44	12.03	8.97	7.48
Per Share Metrics
Diluted EPS TTM	0.69	0.60	0.86	0.84	0.85	0.81	0.28	0.14	-0.02	-0.13	-0.10	-0.18
Free Cash Flow Per Share TTM	0.46	0.12	0.17	0.27	0.38	0.47	0.34	0.29	0.07	0.02	-0.10	-0.23
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	61.27%	57.39%	54.71%	53.00%	52.58%	51.48%	48.93%	46.12%	39.39%	34.44%	30.74%	27.41%
Operating Profit Margin TTM	42.14%	37.53%	34.19%	32.82%	33.10%	32.59%	30.01%	25.42%	15.63%	8.38%	0.57%	-8.01%
Net Profit Margin TTM	32.43%	28.80%	42.87%	44.06%	45.01%	46.35%	17.80%	10.53%	-1.29%	-10.94%	-9.74%	-19.36%
Growth Metrics
Net Revenue Growth (1Y)	10.99%	19.63%	27.63%	43.58%	62.22%	65.15%	63.39%	58.69%	55.68%	67.59%	79.56%	89.07%
Net Income Growth (1Y)	-20.03%	-25.67%	207.41%	500.56%	-5,774.29%	-800.00%	-398.48%	-186.34%	-92.36%	-57.15%	-67.54%	-44.91%
EPS Growth (1Y)	-19.45%	-27.30%	202.21%	477.99%	-5,561.88%	-772.65%	-386.65%	-182.73%	-92.59%	-62.14%	-71.70%	-51.42%
Valuation Metrics
P/E TTM	12.86	29.58	16.70	21.05	22.81	20.22	68.82	74.69	-414.54	-35.85	-35.33	-20.39
P/B TTM	5.45	9.11	8.11	11.04	12.63	11.45	20.22	13.80	9.83	7.49	5.33	5.60
P/S TTM	4.17	8.52	7.16	9.27	10.27	9.37	12.25	7.87	5.33	3.92	3.44	3.95
Market Cap	2.13B	4.35B	3.50B	4.40B	4.72B	4.00B	4.69B	2.60B	1.51B	1.01B	806.49M	821.70M
Enterprise Value	2.19B	4.33B	3.51B	4.31B	4.65B	3.97B	4.60B	2.51B	1.47B	961.03M	732.33M	759.19M
Calculated Values
Free Cash Flow TTM	107.90M	27.82M	40.73M	65.77M	90.64M	110.45M	79.39M	66.64M	16.13M	4.03M	-23.50M	-51.39M
Net Debt	58.71M	-15.49M	11.04M	-90.29M	-71.63M	-30.81M	-86.71M	-88.24M	-45.33M	-51.35M	-74.16M	-62.51M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-27Purchase

Owner: Grossman, Jerrold B

Title: -

Shares: 6,400

Price/Share: $7.91

Value: $50,624.00

Shares Owned: 520,284

Relationship: Director

Ownership: Direct

2026-05-12Purchase

Owner: Grossman, Jerrold B

Title: -

Shares: 12,500

Price/Share: $8.01

Value: $100,125.00

Shares Owned: 513,884

Relationship: Director

Ownership: Direct

2026-05-11Purchase

Owner: Grossman, Jerrold B

Title: -

Shares: 12,500

Price/Share: $8.01

Value: $100,125.00

Shares Owned: 501,384

Relationship: Director

Ownership: Direct

2026-03-16Sale

Owner: Grossman, Adam S

Title: President and CEO

Shares: 21,000

Price/Share: $15.16

Value: $318,360.00

Shares Owned: 2,112,777

Relationship: Director,Officer

Ownership: Direct

2026-03-09Sale

Owner: Kestenberg-Messina, Kaitl…

Title: COO and SVP, Compliance

Shares: 10,096

Price/Share: $15.63

Value: $157,800.48

Shares Owned: 466,600

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-27	Grossman, Jerrold B	Director	-	Direct	Purchase	6,400	7.91	$50,624.00	520,284	4
2026-05-12	Grossman, Jerrold B	Director	-	Direct	Purchase	12,500	8.01	$100,125.00	513,884	4
2026-05-11	Grossman, Jerrold B	Director	-	Direct	Purchase	12,500	8.01	$100,125.00	501,384	4
2026-03-16	Grossman, Adam S	Director,Officer	President and CEO	Direct	Sale	21,000	15.16	$318,360.00	2,112,777	4
2026-03-09	Kestenberg-Messina, Kaitl…	Officer	COO and SVP, Compliance	Direct	Sale	10,096	15.63	$157,800.48	466,600	4
2026-03-06	Elms, Steve	Director	-	Indirect	Purchase	7,000	15.39	$107,730.00	2,045,730	4
2026-02-17	Grossman, Adam S	Director,Officer	President and CEO	Direct	Sale	21,000	16.08	$337,680.00	2,284,379	4
2025-12-15	Grossman, Adam S	Director,Officer	President and CEO	Direct	Sale	21,000	19.79	$415,590.00	2,007,850	4
2025-11-19	Grossman, Adam S	Director,Officer	President and CEO	Direct	Sale	21,000	16.00	$336,000.00	2,013,850	4
2025-10-24	Grossman, Adam S	Director,Officer	President and CEO	Direct	Sale	21,000	16.00	$336,000.00	2,019,850	4
2025-09-15	Grossman, Adam S	Director,Officer	President and CEO	Direct	Sale	21,000	16.13	$338,730.00	2,025,850	4
2025-08-15	Grossman, Adam S	Director,Officer	President and CEO	Direct	Sale	21,000	16.88	$354,480.00	2,031,850	4
2025-07-15	Grossman, Adam S	Director,Officer	President and CEO	Direct	Sale	21,000	18.66	$391,860.00	2,037,850	4
2025-06-16	Grossman, Adam S	Director,Officer	President and CEO	Direct	Sale	21,000	20.81	$437,010.00	2,043,850	4
2025-06-16	Elms, Steve	Director	-	Direct	Sale	194,749	20.24	$3,941,719.76	87,330	4
2025-06-09	Grossman, Jerrold B	Director	-	Direct	Sale	10,000	21.31	$213,100.00	478,194	4
2025-06-09	Guiheen, Lawrence P.	Director	-	Direct	Sale	20,000	20.96	$419,200.00	94,830	4
2025-05-22	Guiheen, Lawrence P.	Director	-	Direct	Sale	1,221	20.12	$24,566.52	114,830	4
2025-05-15	Grossman, Adam S	Director,Officer	President and CEO	Direct	Sale	21,000	19.45	$408,450.00	2,049,850	4
2025-04-15	Grossman, Adam S	Director,Officer	President and CEO	Direct	Sale	21,000	21.46	$450,660.00	2,055,850	4
2025-03-19	Grossman, Adam S	Director,Officer	President and CEO	Direct	Sale	21,000	18.92	$397,320.00	2,061,850	4
2024-11-22	Tade, Brad L.	Officer	CFO and Treasurer	Direct	Sale	15,000	21.15	$317,250.00	199,433	4
2024-11-22	Grossman, Adam S	Director,Officer	President and CEO	Direct	Sale	48,967	21.10	$1,033,203.70	1,989,007	4
2024-09-09	Guiheen, Lawrence P.	Director	-	Direct	Sale	9,000	18.47	$166,230.00	153,941	4
2024-08-30	Kestenberg-Messina, Kaitl…	Officer	COO and SVP, Compliance	Direct	Sale	24,150	16.90	$408,135.00	449,088	4
2024-08-29	Grossman, Jerrold B	Director	-	Direct	Sale	136,861	17.27	$2,363,589.47	467,305	4
2024-08-27	Grossman, Adam S	Director,Officer	President and CEO	Direct	Sale	389,356	17.29	$6,731,965.24	2,059,726	4
2024-08-23	Kwon, Young	Director	-	Direct	Sale	60,000	18.26	$1,095,600.00	241,441	4
2024-06-14	Grossman, Adam S	Director,Officer	President,CEO, and Interim CFO	Direct	Sale	100,000	10.72	$1,072,000.00	2,081,475	4
2024-03-19	Elms, Steve	Director	-	Indirect	Sale	411,829	6.08	$2,503,920.32	2,115,671	4
2024-03-15	Elms, Steve	Director	-	Indirect	Sale	183,008	6.01	$1,099,878.08	2,577,387	4
2023-08-30	Grossman, Jerrold B	Director	-	Direct	Purchase	130,000	3.71	$482,300.00	443,265	4
2023-08-24	Kwon, Young	Director	-	Direct	Purchase	25,000	3.90	$97,500.00	277,401	4
2023-08-22	Fong, Bryant	Director	-	Indirect	Sale	1,433,304	3.87	$5,546,886.48	0	4
2023-08-18	Grossman, Adam S	Director,Officer	President and CEO	Direct	Sale	250,000	4.15	$1,037,500.00	2,273,085	4
2023-08-16	Grossman, Adam S	Director,Officer	President and CEO	Direct	Sale	3	4.39	$13.17	2,523,085	4
2023-08-16	Lenz, Brian	Officer	EVP, CFO	Direct	Sale	178,184	4.45	$792,918.80	782,013	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

86.23%

Inst. Shares: 203,553,999

Shares Outstanding: 236,072,751

2025-12-31

88.93%

Inst. Shares: 211,916,408

Shares Outstanding: 238,299,024

2025-09-30

88.06%

Inst. Shares: 210,120,665

Shares Outstanding: 238,602,978

2025-06-30

82.02%

Inst. Shares: 198,066,135

Shares Outstanding: 241,490,715

2025-03-31

82.27%

Inst. Shares: 195,606,585

Shares Outstanding: 237,775,476

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	203,553,999	236,072,751	86.23%
2025-12-31	211,916,408	238,299,024	88.93%
2025-09-30	210,120,665	238,602,978	88.06%
2025-06-30	198,066,135	241,490,715	82.02%
2025-03-31	195,606,585	237,775,476	82.27%
2024-12-31	195,720,075	233,084,236	83.97%
2024-09-30	199,544,443	234,571,376	85.07%
2024-06-30	175,895,441	232,417,645	75.68%
2024-03-31	170,383,309	228,874,847	74.44%
2023-12-31	166,141,497	223,977,315	74.18%
2023-09-30	167,521,047	225,276,980	74.36%
2023-06-30	162,547,712	222,683,393	72.99%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

ADMA BIOLOGICS, INC. (ADMA) — SEC Financial Statements & Analysis

ADMA BIOLOGICS, INC. (ADMA) is a biological products, (no diagnostic substances) company, incorporated in DE. ADMA BIOLOGICS, INC. trades on Nasdaq as: ADMA. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), ADMA BIOLOGICS, INC. reported a 10.99% year-over-year revenue growth, a Gross Profit Margin of 61.27% (TTM), a Debt-to-Equity ratio of 0.70x, a Price-to-Sales (P/S) ratio of 4.17x (TTM), a Price-to-Book (P/B) ratio of 5.45 (TTM), at a market cap of $2.13B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 10.99%
Gross Profit Margin TTM: 61.27%
Debt To Equity: 0.70x
P/S TTM: 4.17x
P/B TTM: 5.45
Market Cap: $2.13B

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is ADMA BIOLOGICS, INC. in?

ADMA BIOLOGICS, INC. (ADMA) operates in the Biological Products, (No Diagnostic Substances) industry.

What is ADMA's market cap?

ADMA BIOLOGICS, INC. (ADMA) has a market capitalization of $2.13B as of 2026-03-31.

What is ADMA's P/E ratio?

ADMA BIOLOGICS, INC. (ADMA)'s trailing twelve month P/E ratio is 12.86x as of 2026-03-31.

What exchange does ADMA trade on?

ADMA BIOLOGICS, INC. (ADMA) trades on the Nasdaq.

Where is ADMA BIOLOGICS, INC. incorporated?

ADMA BIOLOGICS, INC. is incorporated in DE.

ADMA BIOLOGICS, INC. (ADMA) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.